ClinicaliQ Trial Snapshot
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) – ACCLAIM-Lp(a) — Active Not Recruiting • Phase III • Cardiology / Cardiovascular • NCT06292013.
- Lepodisiran injection reduces heart attacks and strokes in patients with high lipoprotein(a) levels and existing heart disease.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin). Approximately 1700 additional participants will be enrolled in an addendum to explore Lp(a) lowering with an alternative dosing schema. Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) Interventions: Lepodisiran Sodium, Placebo Lead Sponsor: Eli Lilly and Company Planned Enrollment: 17300 participants